A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Clinical trial NCT07134088 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT07134088
Sponsor: Amgen
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia

Start date: 2025-12-08
Primary completion: 2028-12-05
Enrollment: 104

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.